Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab in unresectable malignant mesothelioma
NCT01649024Phase 2Unknown
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- May 2009
- Primary completion
- Jun 2012
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in malignant mesothelioma, sponsored by Azienda Ospedaliera Universitaria Senese. Status: unknown.
02
Drugs
tremelimumab
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT01649024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649024.